227 related articles for article (PubMed ID: 11794886)
21. Frequency of bone densitometry for osteoporosis?
Kleerekoper M
Postgrad Med; 1999 Nov; 106(6):22. PubMed ID: 10575998
[No Abstract] [Full Text] [Related]
22. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
23. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
24. Raloxifene: a new choice for treating and preventing osteoporosis.
Licata AA; Ciaccia AV; Wong M; Draper MW
Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099
[TBL] [Abstract][Full Text] [Related]
25. [Antiestrogen therapy in the treatment of breast neoplasms].
Alba E; Ragonesi G; Colla F; Mazzoleni A; Farina C
Minerva Ginecol; 2002 Jun; 54(3):245-51. PubMed ID: 12063440
[TBL] [Abstract][Full Text] [Related]
26. Building bone.
Depree P
Adv Nurse Pract; 2000 Jan; 8(1):36-8. PubMed ID: 11011593
[No Abstract] [Full Text] [Related]
27. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
Sporn MB; Dowsett SA; Mershon J; Bryant HU
Clin Ther; 2004 Jun; 26(6):830-40. PubMed ID: 15262454
[TBL] [Abstract][Full Text] [Related]
28. Medications for postmenopausal osteoporosis prevention.
Harv Womens Health Watch; 2002 Dec; 10(4):6-7. PubMed ID: 12499127
[No Abstract] [Full Text] [Related]
29. ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.
Curtiss FR
J Manag Care Pharm; 2003; 9(2):178-81. PubMed ID: 14613350
[No Abstract] [Full Text] [Related]
30. Skeletal and nonskeletal effects of raloxifene.
Gluck O; Maricic M
Curr Osteoporos Rep; 2003 Dec; 1(3):123-8. PubMed ID: 16036075
[TBL] [Abstract][Full Text] [Related]
31. Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?
Papadokostakis G; Katonis P; Damilakis J; Hadjipavlou A
Eur Spine J; 2005 Dec; 14(10):977-81. PubMed ID: 15834592
[TBL] [Abstract][Full Text] [Related]
32. A 60-year-old woman trying to discontinue hormone replacement therapy.
Grady D
JAMA; 2002 Apr; 287(16):2130-7. PubMed ID: 11966388
[No Abstract] [Full Text] [Related]
33. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
34. Can the prophylactic use of raloxifene, a selective estrogen-receptor modulator, prevent bone mineral loss and fractures in women with diagnosed osteoporosis or vertebral fractures?
Rosenfeld JA
West J Med; 2000 Sep; 173(3):186-8. PubMed ID: 10986186
[No Abstract] [Full Text] [Related]
35. Raloxifene and risk of vertebral fracture in postmenopausal women.
Halbekath J; Becker-Brüser W; Wille H
JAMA; 2000 May; 283(17):2236-7. PubMed ID: 10807376
[No Abstract] [Full Text] [Related]
36. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
37. Rheumatology: 15. Osteoporosis.
Wade JP
CMAJ; 2001 Jul; 165(1):45-50. PubMed ID: 11468955
[No Abstract] [Full Text] [Related]
38. [Raloxifene - an unexploited possibility of prevention and treatment of postmenopausal osteoporosis].
Štěpán J; Rosa J; Pavelka K
Vnitr Lek; 2016; 62(10):781-788. PubMed ID: 27900864
[TBL] [Abstract][Full Text] [Related]
39. Managing menopause after breast cancer: balancing risks and benefits.
Moore HC
Cleve Clin J Med; 2001 Mar; 68(3):243-8. PubMed ID: 11263852
[TBL] [Abstract][Full Text] [Related]
40. How does raloxifene reduce fracture risk?
McClung MR
Menopause; 2002; 9(5):306-8. PubMed ID: 12218718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
